Norinchukin Bank The Buys 860 Shares of Humana Inc. $HUM

Key Points

• Norinchukin Bank The has increased its stake in Humana Inc. by 15.6%, now holding 6,388 shares valued at approximately $1.69 million.
• Humana's stock has recently seen a 1.9% increase, with a current trading price of $300.01 and a market capitalization of $36.08 billion.
• The company reported an EPS of $6.27 for the last quarter, missing analysts' estimates, while its revenue was up 9.6% year-over-year at $32.39 billion.

Norinchukin Bank The boosted its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 15.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,388 shares of the insurance provider's stock after acquiring an additional 860 shares during the period. Norinchukin Bank The's holdings in Humana were worth $1,690,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC lifted its position in Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after acquiring an additional 46 shares during the period. Riverview Trust Co purchased a new position in Humana in the first quarter worth about $34,000. Garde Capital Inc. purchased a new position in Humana in the first quarter worth about $36,000. Zions Bancorporation National Association UT purchased a new position in Humana in the first quarter worth about $37,000. Finally, Whipplewood Advisors LLC raised its holdings in Humana by 639.1% in the first quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock worth $45,000 after buying an additional 147 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $290.00 target price on shares of Humana in a report on Thursday, May 1st. Morgan Stanley decreased their target price on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a report on Thursday, July 31st. Barclays set a $275.00 price objective on shares of Humana and gave the company an "equal weight" rating in a report on Thursday, July 31st. Royal Bank Of Canada boosted their price objective on shares of Humana from $283.00 to $322.00 and gave the company an "outperform" rating in a report on Thursday, August 21st. Finally, Piper Sandler decreased their price objective on shares of Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a report on Thursday, July 31st. Seven equities research analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $283.29.

Humana Stock Performance

HUM stock traded down $1.57 during midday trading on Wednesday, reaching $297.30. 854,723 shares of the company's stock traded hands, compared to its average volume of 1,711,069. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $382.72. The stock has a market cap of $35.76 billion, a P/E ratio of 22.82, a PEG ratio of 1.75 and a beta of 0.44. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The stock's 50-day moving average is $250.98 and its 200 day moving average is $253.78.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The firm had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The business's revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Friday, September 26th. Humana's dividend payout ratio is presently 27.17%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.